# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Higuchi Ichiyō (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI029-SYN
- Date: 2026-10-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Aiko Lindgren-Tanaka, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

End-of-treatment review after six months. **S**

## History of present illness

Ms. Higuchi returns having completed treatment five days ago: all 182 doses were observed by video, 56 in the intensive phase and 126 in the continuation phase, with none missed. The two-month sputum culture showed no growth. She has had no cough, fever or night sweats for four months and has gained 5.5 kg since intake. She has had no nausea, yellowing, numbness or change in vision. The cystitis in the summer did not return. The public health center has told her that its contact investigation is complete. She writes each morning and has finished two stories since the summer. Her cervical cytology was normal. **S**

| Element | Detail |
|---|---|
| Treatment | 182 of 182 doses observed; completed five days ago |
| Bacteriology | Two-week and two-month cultures negative |
| Weight | 44.0 kg, up 5.5 kg from intake |
| Writing | Two new stories finished |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Respiratory | Negative | No cough, sputum or breathlessness |
| Constitutional | Negative | No fever, night sweats or weight loss |
| Gastrointestinal | Negative | No nausea or jaundice |
| Neurological | Negative | No numbness or tingling |
| Psychiatric | Negative | Mood good; PHQ-9 3 |

5 systems reviewed. **S**

## Current medications

- No current medications. **S**

## Allergies

- No known allergy **S**

## Objective

BP 106/68 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 98% on room air; weight 44 kg; BMI 20.1 kg/m². All vital signs are synthetic.

ALT: 18 U/L; AST: 20 U/L; Albumin: 4.2 g/dL; Hemoglobin: 13.2 g/dL; PHQ-9: 3. All results are synthetic.

## Change since baseline

- ALT: 12 U/L at baseline, 18 U/L at this visit **S**
- AST: 19 U/L at baseline, 20 U/L at this visit **S**
- Albumin: 3.3 g/dL (low) at baseline, 4.2 g/dL at this visit **S**
- Hemoglobin: 11.4 g/dL (low) at baseline, 13.2 g/dL at this visit **S**
- PHQ-9: 8 at baseline, 3 at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), dose 2 of 2 **S**
- Human papillomavirus 9-valent vaccine, dose 2 of 3 **S**
- Influenza vaccine, inactivated, trivalent, preservative-free **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 44.0 kg, BMI 20.1; temperature 36.5 °C, pulse 72, blood pressure 106/68 |
| Eyes | No icterus |
| Respiratory | Clear on both sides |
| Abdomen | Soft; liver not enlarged |
| Neurological | Normal sensation and reflexes in the feet |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Pulmonary tuberculosis, treatment completed** (A15.0). Treatment completed with full observed adherence, culture conversion by two weeks, clinical cure, and normal liver tests throughout. The chest X-ray shows the right upper lobe opacities cleared, leaving a few linear scars; it is kept as her new baseline. Relapse after a fully observed course for drug-susceptible disease is uncommon, so no routine sputum follow-up is needed. **S**
   - Stop isoniazid, rifampin and pyridoxine.
   - Return for a cough lasting more than two to three weeks, fevers, night sweats or weight loss, and tell future clinicians she has been treated for tuberculosis.
   - The orange color of urine and tears will fade within days.
   - Hormonal contraception becomes reliable again about four weeks after the last rifampin dose.
2. **Moderate protein-calorie malnutrition, resolved** (E44.0). Weight 44.0 kg, BMI 20.1, albumin 4.2 g/dL, hemoglobin 13.2 g/dL. **S**
   - Stop the supplement drinks; keep three meals a day.
3. **Low income** (Z59.6). Public funding has ended with treatment; she has paid her clinic charges in instalments. **S**
   - Social worker review of her health insurance premiums and any further help.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, fever, night sweats | At least monthly during treatment | Completed today | No symptoms for four months |
| Self-management | Weight and nutrition | Every visit; dose review if weight changes by more than about 5 kg | Completed today | 44.0 kg, BMI 20.1; albumin 4.2 g/dL |
| Medication safety | Hepatitis symptom review (nausea, vomiting, abdominal pain, jaundice, dark urine) | Every visit and every observed dose | Completed today | No symptoms throughout the continuation phase |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline; at two weeks and monthly in the intensive phase because of low weight and albumin; then for symptoms | Completed today | ALT 18, AST 20 U/L at the end of treatment; no tests were needed for symptoms in the continuation phase |
| Laboratory | Two-month sputum smear and culture | At the end of the intensive phase | Completed today | Smear negative; no growth at six weeks, as with the two-week culture |
| Laboratory | Blood count | At diagnosis, then as needed | Completed today | Hemoglobin 13.2 g/dL, normal |
| Imaging | Chest X-ray | At diagnosis and at the end of treatment as a new baseline | Completed today | Opacities cleared, with a few linear scars; new baseline |
| Medication safety | Doses observed and missed (video-observed therapy) | Every visit | Completed today | 182 of 182 doses observed; treatment completed |
| Medication safety | Peripheral neuropathy check, with pyridoxine | Every visit | Completed today | No neuropathy; pyridoxine stopped with isoniazid |
| Imaging | Visual acuity and color vision | Baseline and monthly while on ethambutol | Not indicated | Ethambutol stopped in the fifth week; acuity normal at two months |
| Referral | Contact investigation (household and close contacts) | Led by the public health center, from diagnosis | Completed today | The public health center reports the investigation complete; results are held in the contacts' own records |
| Referral | Report of treatment outcome to the public health center | At the end of treatment | Completed today | Treatment completed reported |
| Survey | Depression screen (PHQ-9) | At diagnosis, at two months, and at the end of treatment | Completed today | PHQ-9 3, item 9 scored 0 |
| Self-management | Hepatitis B, HPV and influenza vaccines | Hepatitis B in two doses four weeks or more apart; HPV in three doses; influenza each autumn | Completed today | Hepatitis B dose 2 (series complete), HPV dose 2 and influenza vaccine given today; HPV dose 3 due in four months |

## Goal progress

- Complete 182 daily doses within about six and a half months by video-observed therapy. Outcome by 2026-10-20: All 182 doses completed in 26 weeks: 56 in the intensive phase and 126 in the continuation phase, none missed. **S**
- Sputum culture negative at two months. Outcome by 2026-10-20: The cultures taken at two weeks and at two months both showed no growth after six weeks. **S**
- Weight at least 44 kg (BMI about 20) by the end of treatment. Outcome by 2026-10-20: 44.0 kg at the end of treatment, from 38.5 kg at intake. **S**
- Keep writing on a paced schedule without losing income during treatment. Outcome by 2026-10-20: Public funding covered most treatment costs; she kept writing about two hours a day and finished new work. **S**
- No drug-induced liver injury or loss of vision during treatment. Outcome by 2026-10-20: Liver tests normal throughout; visual acuity unchanged. **S**

## Guideline basis

- Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016), American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America (Clinical Infectious Diseases 2016;63(7):e147-e195)
- Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline (2025), American Thoracic Society, Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America (American Journal of Respiratory and Critical Care Medicine 2025;211(1):15-33)
- WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment (2022), World Health Organization
- An official ATS statement: hepatotoxicity of antituberculosis therapy (2006), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine)
- Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- 結核 (Tuberculosis): notification criteria under Article 12 of the Infectious Diseases Control Law (current), Ministry of Health, Labour and Welfare, Japan
- Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012), Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition (JPEN)
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- No routine tuberculosis follow-up; return for symptoms. HPV dose 3 in four months. Next preventive visit in about ten months. **S**

